Clinician beliefs and attitudes about buprenorphine/naloxone diversion

American Journal on Addictions

Volumn 22, Issue 6, 2013, Pages 574-580

  Schuman Olivier, Zev ^a,b   Connery, Hilary ^a   Griffin, Margaret L ^a   Wyatt, Steve A ^c   Wartenberg, Alan A ^d   Borodovsky, Jacob ^d   Renner Jr , John A ^e   Weiss, Roger D ^a  

^a MCLEAN HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MIDDLESEX HOSPITAL   (United States)

^d TUFTS UNIVERSITY   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE PLUS NALOXONE;

ADULT; AGED; ARTICLE; CHILD SAFETY; CHRONIC PAIN; DRUG INTOXICATION; DRUG TRAFFIC; EPIDEMIC; FEMALE; HEALTH BELIEF; HEALTH CARE SURVEY; HEALTH HAZARD; HUMAN; MALE; MEDICAL EDUCATION; NORMAL HUMAN; OPIATE ADDICTION; PHYSICIAN ATTITUDE; PRESCRIPTION;

ADULT; AGED; ANALGESICS, OPIOID; ATTITUDE OF HEALTH PERSONNEL; BUPRENORPHINE; DRUG OVERDOSE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NALOXONE; OPIATE SUBSTITUTION TREATMENT; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUG DIVERSION; REGRESSION ANALYSIS; UNITED STATES;

EID: 84885959369     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1111/j.1521-0391.2013.12024.x     Document Type: Article

References (33)

1. Ling W, Amass L, Shoptaw S, et al. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005; 100: 1090-1100.
2. Mattick RP, Kimber J, Breen C, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008; CD002207.
3. Maryland U., Number of U.S. emergency department visits related to nonmedical use of buprenorphine more than triples since 2006. CESAR Fax. 2011; 20.
4. Ferrant O, Papin F, Clin B, et al. Fatal poisoning due to snorting buprenorphine and alcohol consumption. Forensic Sci Int. 2011; 204: e8-e11.
5. Pelissier-Alicot AL, Sastre C, Baillif-Couniou V, et al. Buprenorphine-related deaths: Unusual forensic situations. Int J Legal Med. 2010; 124: 647-651.
6. Reynaud M, Tracqui A, Petit G, et al. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry. 1998; 155: 448-449.
7. Bailey JE, Campagna E, Dart RC., The underrecognized toll of prescription opioid abuse on young children. Ann Emerg Med. 2009; 53: 419-424.
8. McCarty D, Rieckmann T, Green C, et al. Training rural practitioners to use buprenorphine; using The Change Book to facilitate technology transfer. J Subst Abuse Treat. 2004; 26: 203-208.
9. Rieckmann T, Daley M, Fuller BE, et al. Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat. 2007; 32: 207-215.
10. Wallack SS, Thomas CP, Martin TC, et al. Substance abuse treatment organizations as mediators of social policy: Slowing the adoption of a congressionally approved medication. J Behav Health Serv Res. 2010; 37: 64-78.
11. Kleber HD., Methadone maintenance 4 decades later: Thousands of lives saved but still controversial. JAMA. 2008; 300: 2303-2305.
12. Yokell MA, Zaller ND, Green TC, et al. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: An international review. Curr Drug Abuse Rev. 2011; 4: 28-41.
13. Bazazi AR, Yokell M, Fu JJ, et al. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011; 5: 175-180.
14. Hakansson A, Medvedeo A, Andersson M, et al. Buprenorphine misuse among heroin and amphetamine users in Malmo, Sweden purpose of misuse and route of administration. Eur Addict Res. 2007; 13: 207-215.
15. Comer SD, Walker EA, Collins ED., Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology (Berl). 2005; 181: 664-675.
16. Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010; 105: 709-718.
17. Cicero TJ, Surratt HL, Inciardi J., Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007; 3: 302-308.
18. Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: Illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat. 2010; 39: 41-50.
19. Monte AA, Mandell T, Wilford BB, et al. Diversion of buprenorphine/ naloxone coformulated tablets in a region with high prescribing prevalence. J Addict Dis. 2009; 28: 226-231.
20. Lofwall MR, Havens JR., Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012; 126: 379-383.
21. Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend. 2009; 104: 73-77.
22. Bridge TP, Fudala PJ, Herbert S, et al. Safety and health policy considerations related to the use of buprenorphine/naloxone as an office-based treatment for opiate dependence. Drug Alcohol Depend. 2003; 70 (2 Suppl.): S79-S85.
23. Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. Drug Abuse Warning Network, 2008: National Estimates of Drug Related Emergency Department Visits. Publication No. SMA 11-4618; 2011.
24. Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med. 2010; 11: 1078-1091.
25. Geib AJ, Babu K, Ewald MB, et al. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics. 2006; 118: 1746-1751.
26. Hayes BD, Klein-Schwartz W, Doyon S., Toxicity of buprenorphine overdoses in children. Pediatrics. 2008; 121: e782-e786.
27. Pedapati EV, Bateman ST., Toddlers requiring pediatric intensive care unit admission following at-home exposure to buprenorphine/naloxone. Pediatr Crit Care Med. 2011; 12: e102-e107.
28. Schwarz KA, Cantrell FL, Vohra RB, et al. Suboxone (buprenorphine/ naloxone) toxicity in pediatric patients: A case report. Pediatr Emerg Care. 2007; 23: 651-652.
29. Duke AN, Correia CJ, Walsh SL, et al. Acute effects of intramuscular and sublingual buprenorphine and buprenorphine/naloxone in non-dependent opioid abusers. Psychopharmacology (Berl). 2010; 211: 303-312.
30. Middleton LS, Nuzzo PA, Lofwall MR, et al. The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers. Addiction. 2011; 106: 1460-1473.
31. Schepis TS, Krishnan-Sarin S., Sources of prescriptions for misuse by adolescents: Differences in sex, ethnicity, and severity of misuse in a population-based study. J Am Acad Child Adolesc Psychiatry. 2009; 48: 828-836.
32. Strain EC, Harrison JA, Bigelow GE., Induction of opioid-dependent individuals onto buprenorphine and buprenorphine/naloxone soluble-films. Clin Pharmacol Ther. 2011; 89: 443-449.
33. Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial. JAMA. 2010; 304: 1576-1583.